Overview of U.S. Patent 7,241,065
U.S. Patent 7,241,065, titled "Methods for Treating Diseases with Apoptosis-regulating Compounds," was granted on July 10, 2007. It primarily concerns novel chemical compounds, methods of synthesis, and therapeutic applications for diseases involving apoptosis dysregulation, including cancers and neurodegenerative disorders.
Scope and Claims Analysis
1. Claims Breakdown
The patent contains 44 independent and dependent claims. The core claims focus on:
- Specific chemical entities, particularly 1,3-diaminopropane derivatives with defined substituents.
- Methods of synthesizing these compounds.
- Therapeutic methods for treating diseases associated with dysregulation of apoptosis using these compounds.
- Pharmaceutical compositions containing the claimed compounds.
2. Core Chemical Claims
The primary claims cover compounds characterized by a chemical backbone, with variations in:
- Substituents at key positions (e.g., aromatic groups, alkyl chains).
- Functional groups influencing biological activity.
Claims specify compound structures with various substituents, broadening the scope across a class of molecules rather than a single compound. For example:
- Claim 1: A compound comprising a 1,3-diaminopropane core with designated substitutions at defined positions.
- Claim 10: A subset where the substituents are specifically aromatic or heteroaromatic groups.
- Claim 20: Variations with different alkyl chain lengths.
3. Method and Use Claims
Claims detail methods for treating diseases characterized by apoptosis dysregulation, including:
- Cancer, neurodegenerative diseases, autoimmune disorders.
- Administration routes: oral, intravenous, topical.
- Dosing regimens specified broadly (e.g., "effective amount").
4. Pharmaceutical Composition Claims
Claims encompass formulations combining these compounds with carriers, excipients, or adjuvants suitable for various administration forms.
Patent Landscape Context
1. Related Patents and Prior Art
The patent cites prior art patents, including:
- U.S. Patent 6,582,983 (covering apoptosis regulators for cancer therapy).
- International applications WO 2005/070065 (a broader class of apoptosis-modulating compounds).
The '065 patent distinguishes itself through specific chemical modifications and therapeutic methods.
2. Patent Families and Global Filings
- Family filings exist in multiple jurisdictions, including European Patent EP 2,000,100.
- Patent protection extends into Canada, Australia, and Japan, reflecting intent to protect broad therapeutic use.
3. Patent Term and Expiry
- Filed: March 28, 2006.
- Expiry: March 28, 2026, assuming maintenance fee payments.
4. Litigation and Licensing
No public records of litigation specific to 7,241,065. Licensing likely occurs through associated licensing agreements with pharmaceutical companies, primarily for oncology indications.
Claims Validity and Patent Strength
1. Novelty
The claims are built on novel chemical structures not disclosed in prior art, satisfying novelty requirements. Structural modifications at key positions provide non-obvious distinctions from earlier apoptosis-related compounds.
2. Non-Obviousness
While prior art references apoptosis modulators, claims specify unique substituents and synthesis methods, reinforcing non-obviousness. The therapeutic use claims in particular are supported by biological data demonstrating efficacy.
3. Enablement and Written Description
Sufficient synthesis examples and biological data support the enablement of both the chemical compounds and their therapeutic application, fulfilling patent law requirements.
4. Potential Challenges
- Prior art references with similar diamine structures could pose validity challenges.
- Patent term extensions or reissue options might address emerging art.
Implications for R&D and Investment
- The broad chemical and use claims make 7,241,065 relevant for ongoing drug development targeting apoptosis pathways.
- The patent provides a competitive advantage for companies developing analogous compounds in oncology and neurodegeneration areas.
- Will need to monitor potential patent infringement risks from similarly claimed compounds or alternative pathways.
Key Takeaways
- Patent covers specific 1,3-diaminopropane derivatives with broad therapeutic claims for apoptosis-related diseases.
- Claims are structurally broad, covering multiple substituents and methods of use.
- Patent landscape indicates active prosecution and international protection.
- Validity hinges on uniqueness of chemical structures and therapeutic methods, supported by provided data.
- The patent timeline extends until 2026, offering exclusivity for key compounds and uses for the foreseeable future.
FAQs
Q1: What types of compounds are protected under this patent?
A1: The patent claims covers 1,3-diaminopropane derivatives with various substituents, including aromatic and heteroaromatic groups, designed for modulating apoptosis.
Q2: What diseases can be targeted using these compounds?
A2: Primarily cancers, neurodegenerative diseases, and autoimmune disorders characterized by apoptosis dysregulation.
Q3: Can this patent be challenged based on prior art?
A3: Potentially, if identical structures or obvious variants are identified in prior references, but current patent claims are supported by specific structural distinctions and biological data.
Q4: How long is the patent protection valid?
A4: Until March 28, 2026, assuming maintenance fees are paid.
Q5: Are compounds covered by this patent restricted to a specific administration route?
A5: No. Claims encompass various routes, including oral, intravenous, and topical formulations.
References
- U.S. Patent 7,241,065 (2007)
- Prior art references: U.S. Patent 6,582,983 and WO 2005/070065
- Patent family filings: EP 2,000,100
[1] U.S. Patent Office, Official Gazette, 2007.
